【新药】苯巴那酯在美国获批治疗成人局灶性癫痫！

Sodium channel blockers, produced and developed by SK Life Sciences, are believed to reduce the repetitive release of electrical impulses from nerve cells by inhibiting voltage-gated sodium currents and positively regulating GABAA (γ-aminobutyric acid) receptor activity through isomerism. Today let’s take a closer look at Phenobarnate.

Phenobarate was approved for marketing in the United States in November 2019 for the treatment of partial-onset seizures in adults. The drug was discovered and developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Sciences. Phenobarate significantly reduced the frequency of focal-onset epilepsy compared with placebo, and up to 20% of patients achieved zero seizures during the maintenance period. Epileptic seizures are usually brief bursts of abnormal electrical activity in the brain. Phenobarate reduces repetitive neuronal discharges by inhibiting voltage-gated sodium currents. The drug is also a positive allosteric modulator of gamma-aminobutyric acid (GABAA) ion channels.

Phenobarate may be used in combination with other antiepileptic drugs or alone. Phenobarate should be started at 12.5 mg once daily and titrated every 2 weeks. After a drug adjustment period, the recommended maintenance dose is 200 mg/day, but some patients may need to adjust to 400 mg/day, which is the maximum recommended dose. Study 013 included a 6-week titration period and a 6-week maintenance period. Data showed that a 200 mg/day dose of phenobarate reduced the median seizure frequency by 56%, compared with 22% in the placebo group. A post hoc analysis of the maintenance period showed that 28% of patients in the lumbarate treatment group reported zero seizures, compared with 9% in the placebo group.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: